Arrowhead's plozasiran cuts pancreatitis events 78% in Phase 3 data

August 30, 2026 11:30 AM

Arrowhead Pharmaceuticals (NASDAQ: ARWR) presented detailed results from its Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found